{"analyses":[{"ciLowerLimit":"0.60","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.50","estimateComment":"Hazard ratio of panitumumab vs cisplatin","groupDescription":"The log rank test stratified by the stratification factors at randomization was used to compare the difference in PFS between two treatment arms.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.83","paramType":"Hazard Ratio (HR)","paramValue":"0.95","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"43"}],"title":"PFS event"},{"measurements":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"117"}],"title":"no PFS event"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"description":"The progression event is defined by first event of the following,\n\nLocal-regional progression or recurrence Distant metastasis Non-protocol RT, chemotherapy, or biologic therapy without documentation of the site of failure Surgery of primary site with tumour present/unknown Neck dissection with tumour present/unknown, \\> 15 weeks from end of RT Death due to study cancer or from unknown causes or any other reason\n\nNumber of patients with and without progression event will be reported.","groups":[{"description":"Patients undergo standard fractionation radiotherapy (IMRT or 3D CRT) once daily, 5 days a week, for 7 weeks. Patients receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.\n\ncisplatin: Given IV\n\n3-dimensional conformal radiation therapy: Patients undergo radiotherapy\n\nintensity-modulated radiation therapy: Patients undergo radiotherapy","id":"OG000","title":"Cisplatin"},{"description":"Patients undergo accelerated fractionation radiotherapy (IMRT or 3D CRT) once or twice daily, 5 days a week, for 6 weeks. Patients receive panitumumab IV over 30-90 minutes 1 week prior to and on days 15 and 36 of radiotherapy.\n\npanitumumab: Given IV\n\n3-dimensional conformal radiation therapy: Patients undergo radiotherapy\n\naccelerated radiation therapy: Patients undergo accelerated fractionation radiotherapy\n\nintensity-modulated radiation therapy: Patients undergo radiotherapy","id":"OG001","title":"Panitumumab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"6.2 years","title":"Progression-free Survival (PFS) Rate","type":"PRIMARY","unitOfMeasure":"Participants"}